Vascular endothelial growth factor +936C/T polymorphism and cancer risk in Asians: a meta-analysis

X.L. Liu¹,², Q.F. Yang¹,² and B.H. Kong¹,³

¹Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Ji’nan, Shandong, China
²Department of Breast Surgery, Qilu Hospital, Shandong University, Ji’nan, Shandong, China
³Gynecology Oncology Key Library of Shandong Province, Qilu Hospital, Shandong University, Ji’nan, Shandong, China

Corresponding author: B.H. Kong
E-mail: kongbeihua@yahoo.com.cn

Received November 27, 2012
Accepted March 29, 2013
Published June 13, 2013
DOI http://dx.doi.org/10.4238/2013.June.13.1

ABSTRACT. Vascular endothelial growth factor (VEGF), the most important regulator of angiogenesis and vascular permeability, is involved in various steps of carcinogenesis. The +936C/T polymorphism of the VEGF gene has been reported to affect the VEGF protein level and to be related to the susceptibility of cancer. However, the results of published studies, as well as the subsequent meta-analyses, remain contradictory. We investigated the association between VEGF +936C/T polymorphism and cancer risk in the Asian population. Twenty-one papers were selected from the PubMed database after a systematic search. Statistics on the frequencies of CC, CT, and TT genotypes of the VEGF +936C/T gene were collected from 8298 cases and 8053 controls. No significant associations between the VEGF +936C/T polymorphism and cancer risk were found for alleles T vs C [odd ratio (OR) = 0.99, 95% confidence interval (95%CI) = 0.93-1.05], TT vs CT/CC (OR = 1.05, 95%CI = 0.88-1.26), CC vs CT/TT (OR = 1.02, 95%CI = 0.96-1.10), and TT vs CC (OR = 1.05, 95%CI = 0.88-1.25). No significant associations were detected in the subgroup analysis by
cancer type either. The VEGF +936C/T polymorphism is not associated with risk of overall cancer among Asians.

**Key words:** Cancer; Vascular endothelial growth factor; Asian; Single nucleotide polymorphism

**INTRODUCTION**

As we all know, the malignancies are lethal largely due to their advanced stage at diagnosis. Thus, the discovery of genetic factors associated with cancer risk may help lower the stage and improve survival (Bosch et al., 2011; Jelovac and Armstrong, 2011).

Angiogenesis, which plays a pivotal role in carcinogenesis by influencing growth, invasion, and the formation of metastases, is regulated by a balance of pro- and anti-angiogenic factors. Vascular endothelial growth factor (VEGF) is a crucial player in angiogenesis as it represents the principal pro-angiogenic factor. High VEGF levels have been proven to have association with many malignances such as ovarian cancer (Cooper et al., 2002), colorectal cancer (Alabi et al., 2009), and gastric cancer (Ohta et al., 2003).

The human VEGF gene is located on chromosome 6p21.3 and consists of 8 exons separated by 7 introns (Vincenti et al., 1996). Several single nucleotide polymorphisms have been shown to affect the expression of the VEGF gene, including the VEGF +936C/T polymorphism in the 3'-untranslated region of the VEGF gene. Renner et al. (2000) found that +936T allele carriers had significantly lower VEGF plasma levels, suggesting that it could be a genetic marker for angiogenesis-associated disease. To date, a large number of studies have focused on exploring the association between the VEGF +936C/T polymorphism and risk of various types of cancer, including oral, gastric, colorectal, breast, lung, prostate, cervical, and so on. However, the results are conflicting. Taking breast cancer as an example, similar frequencies of VEGF +936C/T genotypes between cases and controls were reported by Jacobs et al. (2006). In contrast, Krippel et al. (2003), Kataoka et al. (2006), and Jakubowska et al. (2008) suggested that VEGF +936T is a protective factor against breast cancer. However, Balasubramanian et al. (2007) found that VEGF +936C was associated with decreased breast cancer risk when combined with -460T and +405C. Meta-analyses also failed to confirm the protective role of VEGF +936T (Gu and Wang, 2011; Yang et al., 2011).

We conducted this meta-analysis to determine if the VEGF +936C/T polymorphism modulates susceptibility in Asians.

**MATERIAL AND METHODS**

**Publication search**

PubMed was searched using the terms “Vascular endothelial growth factor gene polymorphism” and “cancer”. Additional studies were included by a manual inspection of the references cited in the original studies and reviews. Only English-language papers were included.

**Inclusion and exclusion criteria**

All studies that met the inclusion criteria were included in this meta-analysis; if not,
the study was excluded: i) case-control study based on the association between the VEGF +936C/T polymorphism and cancer risk; ii) the study contained detailed information on the frequencies of the CC, CT, and TT genotypes in both cases and controls, and iii) all cases and controls involved were Asians. If the study had the same population resource, only the study reporting the largest population was selected.

Data extraction

We followed a standard protocol for data extraction. For each study, the following information was recorded: first author’s surname, year of publication, country or region, numbers of genotyped cases and controls, and genotyping method.

Statistical analysis

The odds ratios (OR) with 95% confidence intervals (95% CIs) of allele T vs allele C in cases and controls were calculated to assess the strength of the association between the VEGF +936C/T polymorphism and cancer risk, as well as the recessive genetic model (TT vs CT/TT), dominant genetic model (CC vs CT/TT), and homozygote comparison (TT vs CC). Further stratified analyses were also performed in the subgroups sharing the same cancer type and consisting of more than two papers.

We used the Q-statistic to determine the degree of heterogeneity between the trials. P < 0.05 was interpreted as significant heterogeneity. When there was no statistical heterogeneity, we used a fixed-effect model (the Mantel-Haenszel method). If heterogeneity was present, we used a random-effect model (the DerSimonian and Laird method). All statistical analyses were performed with the Stata software (version 11; Stata Corporation, USA). All statistical tests were two-sided.

RESULTS

Characteristics of studies

In total, 21 studies (Abe et al., 2002; Kataoka et al., 2006; Hsiao et al., 2007; Amano et al., 2008; Bae et al., 2008a,b; Chae et al., 2006, 2008; Cheng et al., 2008; Ke et al., 2008; Hsing et al., 2008; Al-Moundhri et al., 2009; Tahara et al., 2009; Wu et al., 2009; Li et al., 2010; Kim et al., 2010; Bao et al., 2011; Beeghly-Fadiel et al., 2011; Kang et al., 2011; Li et al., 2011; Zhou et al., 2011) comprising 8298 cancer cases and 8053 controls were included in the meta-analysis. The VEGF allele +936T frequency was 17.78% in cases and 17.84% in controls. According to the cancer type, we performed subgroup analyses for 6 gastric cancer risk studies and 4 colorectal cancer risk studies. The other characteristics of the studies included in the present meta-analysis are listed in Table 1.

Quantitative synthesis

In the overall analysis, no association could be observed between the VEGF +936C/T polymorphism and cancer risk when all the eligible studies were pooled, as was shown in T vs C (fixed effects, OR = 0.99, 95%CI = 0.93-1.05, P = 0.178) (Figure 1), TT vs CT/CC (fixed
VEGF +936C/T polymorphism and cancer risk

...effects, OR = 1.05, 95%CI = 0.88-1.26, P = 0.090) (Figure 2), CC vs CT/TT (fixed effects, OR = 1.02, 95%CI = 0.96-1.10, P = 0.352) (Figure 3), and TT vs CC (fixed effects, OR = 1.05, 95%CI = 0.88-1.25, P = 0.082) (Figure 4). According to the subgroup analyses by cancer type, there were no significant associations between the VEGF allele +936C/T polymorphism and risk of colorectal cancer and gastric cancer in different genetic comparisons.

**Table 1.** Main characteristics of the eligible studies.

<table>
<thead>
<tr>
<th>No</th>
<th>Reference</th>
<th>Region</th>
<th>Cancer type</th>
<th>Case Nos.</th>
<th>Control Nos.</th>
<th>Genotyping method</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Abe et al., 2002</td>
<td>Japan</td>
<td>Renal cell carcinoma</td>
<td>145</td>
<td>145</td>
<td>PCR-RFLP</td>
</tr>
<tr>
<td>2</td>
<td>Chae et al., 2006</td>
<td>Korea</td>
<td>Gastric cancer</td>
<td>413</td>
<td>413</td>
<td>PCR-RFLP</td>
</tr>
<tr>
<td>3</td>
<td>Kataoka et al., 2006</td>
<td>China</td>
<td>Breast cancer</td>
<td>1109</td>
<td>1195</td>
<td>TaqMan</td>
</tr>
<tr>
<td>4</td>
<td>Hisao et al., 2007</td>
<td>Taiwan</td>
<td>Thyroid cancer</td>
<td>288</td>
<td>232</td>
<td>TaqMan</td>
</tr>
<tr>
<td>5</td>
<td>Amano et al., 2008</td>
<td>Japan</td>
<td>Endometrial carcinoma</td>
<td>105</td>
<td>179</td>
<td>PCR-RFLP</td>
</tr>
<tr>
<td>6</td>
<td>Bae et al., 2008</td>
<td>Korea</td>
<td>Colon cancer</td>
<td>262</td>
<td>229</td>
<td>PCR-RFLP</td>
</tr>
<tr>
<td>7</td>
<td>Bae et al., 2008</td>
<td>Korea</td>
<td>Gastric Cancer</td>
<td>154</td>
<td>229</td>
<td>PCR-RFLP</td>
</tr>
<tr>
<td>8</td>
<td>Ke et al., 2008</td>
<td>China</td>
<td>Gastric cancer</td>
<td>540</td>
<td>561</td>
<td>PCR-RFLP</td>
</tr>
<tr>
<td>9</td>
<td>Hsing et al., 2008</td>
<td>China</td>
<td>Biliary Cancer</td>
<td>407</td>
<td>779</td>
<td>TaqMan</td>
</tr>
<tr>
<td>10</td>
<td>Chae et al., 2008</td>
<td>Korea</td>
<td>Colorectal cancer</td>
<td>465</td>
<td>413</td>
<td>PCR-DHPLC</td>
</tr>
<tr>
<td>11</td>
<td>Cheng et al., 2008</td>
<td>Taiwan</td>
<td>Oral squamous cell carcinoma</td>
<td>218</td>
<td>121</td>
<td>PCR-RFLP</td>
</tr>
<tr>
<td>12</td>
<td>Al-Moundhri et al., 2009</td>
<td>Oman</td>
<td>Gastric Cancer</td>
<td>130</td>
<td>130</td>
<td>PCR-RFLP</td>
</tr>
<tr>
<td>13</td>
<td>Wu et al., 2009</td>
<td>China</td>
<td>Colorectal cancer</td>
<td>157</td>
<td>117</td>
<td>PCR-RFLP</td>
</tr>
<tr>
<td>14</td>
<td>Tahara et al., 2009</td>
<td>Japan</td>
<td>Gastric cancer</td>
<td>385</td>
<td>316</td>
<td>PCR-RFLP</td>
</tr>
<tr>
<td>15</td>
<td>Li et al., 2010</td>
<td>China</td>
<td>Epithelial ovarian cancer</td>
<td>303</td>
<td>303</td>
<td>PCR-RFLP</td>
</tr>
<tr>
<td>16</td>
<td>Kim et al., 2010</td>
<td>Korea</td>
<td>Cervical cancer</td>
<td>198</td>
<td>214</td>
<td>PCR-SSP</td>
</tr>
<tr>
<td>17</td>
<td>Bao et al., 2011</td>
<td>China</td>
<td>Glioma</td>
<td>160</td>
<td>320</td>
<td>PCR-RFLP</td>
</tr>
<tr>
<td>18</td>
<td>Zhou et al., 2011</td>
<td>China</td>
<td>Gastric cancer</td>
<td>150</td>
<td>150</td>
<td>PCR-RFLP</td>
</tr>
<tr>
<td>19</td>
<td>Li et al., 2011</td>
<td>China</td>
<td>Breast cancer</td>
<td>1901</td>
<td>1801</td>
<td>TaqMan</td>
</tr>
<tr>
<td>20</td>
<td>Beeghly-Fadial et al., 2011</td>
<td>China</td>
<td>Glioma</td>
<td>758</td>
<td>798</td>
<td>MassARRAY</td>
</tr>
<tr>
<td>21</td>
<td>Kang et al., 2011</td>
<td>Korea</td>
<td>Colorectal cancer</td>
<td>50</td>
<td>50</td>
<td>PCR-RFLP</td>
</tr>
</tbody>
</table>

TaqMan (Applied Biosystems, Foster City, CA, USA) and MassARRAY (Sequenom, San Diego, CA, USA) are commercial systems for single nucleotide polymorphism genotyping; PCR = polymerase chain reaction; RFLP = restriction fragment length polymorphism; DHPLC = denaturing high-performance liquid chromatography. *Data of Chae et al. (2006) were combined in analyses, since the articles share the same control subjects.* \[1\] Data of Bae et al. (2008) were combined in analyses, since the articles share the same control subjects. \[2\] Data of Beeghly-Fadial et al. (2011) and Kang et al. (2011) were obtained by e-mail contact. \[3\] Beeghly-Fadial et al. (2011) provided genotyping information of 2261 participants from the SBCS I (Shanghai Breast Cancer Study, 1996-1998) and 3702 participants from the SBCS II (2002-2005). Since Kataoka et al. (2006) reported larger population based on SBCS I, only 3702 participants of this article were involved in this meta-analysis.

**Figure 1.** Forest plot of overall cancer risk associated with the VEGF +936C/T polymorphism (T vs C). OR = odds ratio; 95%CI = 95% confidence interval.
**Figure 2.** Forest plot of overall cancer risk associated with the VEGF +936C/T polymorphism (TT vs CT/CC). OR = odds ratio; 95%CI = 95% confidence interval.

**Figure 3.** Forest plot of overall cancer risk associated with the VEGF +936C/T polymorphism (CC vs CT/TT). OR = odds ratio; 95%CI = 95% confidence interval.

**Figure 4.** Forest plot of overall cancer risk associated with the VEGF +936C/T polymorphism (TT vs CC). OR = odds ratio; 95%CI = 95% confidence interval.
Publication bias

The publication bias of the studies was assessed by Begg’s funnel plot and the Egger test. As shown in Figures 5-8, the shapes of the funnel plots did not reveal any obvious asymmetry, indicating the absence of publication bias in the studies. Subsequently, the Egger test was used to provide statistical evidence of the symmetry. As expected, the result revealed no obvious evidence of publication bias (t = 1.05, P = 0.307 in T vs C).

**Figure 5.** Begg’s funnel plot for publication bias test (T vs C). SE = standard error; OR = odds ratio.

**Figure 6.** Begg’s funnel plot for publication bias test (TT vs CT/CC). SE = standard error; OR = odds ratio.
DISCUSSION

In our meta-analysis, no association between the VEGF +936C/T gene polymorphism with cancer risk was found among the Asian population. Subgroup analyses stratified by cancer type were also performed, and did not reveal any genotype differences between cases and controls (Table 2).

Figure 7. Begg’s funnel plot for publication bias test (CC vs CT/TT). SE = standard error; OR = odds ratio.

Figure 8. Begg’s funnel plot for publication bias test (TT vs CC). SE = standard error; OR = odds ratio.
The exact mechanism for how VEGF +936C/T acted on the carcinogenic procedure was not clear. In recent years, intense genetic research efforts have been made in this field, and the results produced have been conflicting (Krippl et al., 2003; Jacobs et al., 2006; Kataoka et al., 2006; Balasubramanian et al., 2007; Jakubowska et al., 2008). The leading potential explanation for the association was that the DNA sequence variation may alter VEGF production and/or activity (Renner et al., 2000), thereby causing differences in the development of tumors (Kim et al., 2010). However, Bae et al. (2008b) believed that VEGF-related functions such as thrombosis (Verheul et al., 2000; Eroglu et al., 2007) made sense, instead of angiogenesis. The most confusing question was if the genetic association does exist, why could we not find the difference? First, the VEGF polymorphism may exert varying effects on various cancers, and the combined studies diminished the differences. Second, other VEGF genes could have interacted with VEGF +936C/T, thus affecting the VEGF serum level and being involved in the carcinogenesis. Third, as the pathogenesis of cancer is regulated by many factors, it is possible that other related genes and environmental factors (Xu et al., 2010) predominated in the development of cancer and obscured the role of VEGF +936C/T.

At the same time, Ke et al. (2008) suggested that VEGF is perhaps more likely to affect tumor biological behavior, such as tumor growth, invasion, and metastasis than it is in defining susceptibility to tumors. Thus, the VEGF +936C/T polymorphism appeared to be more effective in predicting the prognosis, rather than the cancer risk. In addition, Renner et al. (2000) believed that the 936C/T polymorphism could result in linkage disequilibrium with another yet unidentified functional polymorphism elsewhere and tolerated type II error in the studies. Moreover, the insufficient statistic power, stemming from the small sample size (Jain et al., 2009), also contributed to the inconsistence among the studies.

The limitations of this meta-analysis should be addressed. First, the controls in the studies included were not uniformly defined. As a result, the statistics presented here were based on unadjusted estimates. A more precise analysis could be conducted adjusted by other co-variants, such as age, gender, lifestyle, and environmental factors. Second, the size of each subgroup with the same cancer type was too small to provide adequate statistical power to detect further associations. Third, VEGF gene polymorphisms other than VEGF +936C/T may

<table>
<thead>
<tr>
<th>Cancer type</th>
<th>Gastric cancer</th>
<th>Colorectal cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases/controls</td>
<td>1772/1799</td>
<td>934/809</td>
</tr>
<tr>
<td>T vs C</td>
<td>OR (95%CI)</td>
<td>1.03 (0.84-1.26)</td>
</tr>
<tr>
<td>P</td>
<td>0.004</td>
<td>0.171</td>
</tr>
<tr>
<td>TT vs CT/CC</td>
<td>OR (95%CI)</td>
<td>1.06 (0.71-1.58)</td>
</tr>
<tr>
<td>P</td>
<td>0.168</td>
<td>0.416</td>
</tr>
<tr>
<td>CC vs CT/TT</td>
<td>OR (95%CI)</td>
<td>1.00 (0.92-1.08)</td>
</tr>
<tr>
<td>P</td>
<td>0.011</td>
<td>0.162</td>
</tr>
<tr>
<td>TT vs CC</td>
<td>OR (95%CI)</td>
<td>1.05 (0.70-1.56)</td>
</tr>
<tr>
<td>P</td>
<td>0.095</td>
<td>0.396</td>
</tr>
</tbody>
</table>

*P = Q-statistic for heterogeneity. The random-effect model (DerSimonian-Laird method) was used when P < 0.05; the fixed-effect model (Mantel-Haenszel method) was used otherwise. OR = odds ratio; 95%CI = 95% confidence interval.
have a combined effect with it, which we could not detect. The limited data available from studies on other gene polymorphisms were the main reason we restricted this meta-analysis to the VEGF +936C/T polymorphism.

In conclusion, the results of our meta-analysis provided evidence that the VEGF +936C/T polymorphism was not associated with overall cancer risk in Asians. Neither did the subgroups of colorectal and gastric cancer exhibit any associations between the VEGF allele +936T and cancer risk. Further, well-designed large epidemiological studies are warranted to validate our findings.

ACKNOWLEDGMENTS

The authors thank X.N. Kong for her support in the analysis, and special thanks to A. Beeghly-Fadiel and M.J. Kang for providing the detailed data of their researches.

REFERENCES


Hsiao PJ, Lu MY, Chiang FY, Shin SJ, et al. (2007). Vascular endothelial growth factor gene polymorphisms in thyroid...


